HK1153136A1 - - Google Patents
Info
- Publication number
- HK1153136A1 HK1153136A1 HK11107242.8A HK11107242A HK1153136A1 HK 1153136 A1 HK1153136 A1 HK 1153136A1 HK 11107242 A HK11107242 A HK 11107242A HK 1153136 A1 HK1153136 A1 HK 1153136A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hydroxybenzoyl
- butanoate
- insulin
- chloro
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34761002P | 2002-01-09 | 2002-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1153136A1 true HK1153136A1 (xx) | 2012-03-23 |
Family
ID=23364463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107242.8A HK1153136A1 (xx) | 2002-01-09 | 2011-07-12 |
Country Status (8)
Country | Link |
---|---|
US (5) | US7227033B2 (xx) |
EP (2) | EP2272501B1 (xx) |
JP (1) | JP4508646B2 (xx) |
AU (1) | AU2003223158B2 (xx) |
CA (1) | CA2471144C (xx) |
ES (2) | ES2664189T3 (xx) |
HK (1) | HK1153136A1 (xx) |
WO (1) | WO2003057650A2 (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4508646B2 (ja) * | 2002-01-09 | 2010-07-21 | エミスフェアー・テクノロジーズ・インク | 4−[(4−クロロ−2−ヒドロキシベンゾイル)アミノ]ブタン酸ナトリウムの多形体 |
JP5452843B2 (ja) * | 2003-01-06 | 2014-03-26 | エミスフィアー テクノロジーズ インコーポレイテッド | 夜間の経口インスリン治療 |
US20050203001A1 (en) * | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
NZ551196A (en) * | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
MXPA06013295A (es) | 2004-05-19 | 2007-02-22 | Emisphere Tech Inc | Formulaciones de aciclovir. |
MXPA06013384A (es) | 2004-05-19 | 2007-03-01 | Emisphere Tech Inc | Formulaciones topicas de cromolin. |
WO2006017541A2 (en) * | 2004-08-03 | 2006-02-16 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
GB0427603D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
GB0427600D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
MX2007008082A (es) * | 2004-12-29 | 2007-09-05 | Emisphere Tech Inc | Formulaciones farmaceuticas de sales de galio. |
US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
US8030271B2 (en) | 2005-07-05 | 2011-10-04 | Emisphere Technologies, Inc. | Compositions and methods for buccal delivery of human growth hormone |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
WO2008003050A2 (en) * | 2006-06-28 | 2008-01-03 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
JP5985985B2 (ja) | 2009-08-03 | 2016-09-06 | エミスフィアー テクノロジーズ インコーポレイテッドEmisphere Technologies,Inc. | 胃腸への影響が減少した即効型ナプロキセン組成物 |
BR112015006176B1 (pt) | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular |
MX360107B (es) | 2012-11-13 | 2018-10-23 | Adocia | Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido. |
US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
FR3020947B1 (fr) * | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
CN113167568B (zh) * | 2018-11-29 | 2023-04-28 | 日本电气方案创新株式会社 | 坐标计算装置、坐标计算方法和计算机可读记录介质 |
CN111925298B (zh) * | 2020-09-02 | 2023-05-30 | 无锡紫杉药业有限公司 | 一种4-cnab及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5811856B2 (ja) * | 1975-07-14 | 1983-03-04 | 中外製薬株式会社 | 2 4− ビス (2’ − アセトキシベンズアミド ) アンソクコウサンノ イケイケツシヨウノ セイゾウホウ |
JPS5312417A (en) * | 1976-07-20 | 1978-02-03 | Sumitomo Chem Co Ltd | Preparation of amorphous d rugs |
US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
DE3266360D1 (en) * | 1981-06-16 | 1985-10-24 | Choay Sa | Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation |
USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
US5583020A (en) * | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
US5401516A (en) | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
EP1025840B1 (en) | 1993-04-22 | 2005-06-29 | Emisphere Technologies, Inc. | Oral drug compositions |
US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
JP3462895B2 (ja) * | 1993-11-05 | 2003-11-05 | 三井化学株式会社 | 安息香酸誘導体の多価金属塩の製造方法 |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
US5776888A (en) | 1997-02-07 | 1998-07-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO1998034632A1 (en) | 1997-02-07 | 1998-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
GB9808896D0 (en) * | 1998-04-25 | 1998-06-24 | Smithkline Beecham Plc | Novel compound |
PL200710B1 (pl) * | 1998-06-19 | 2009-01-30 | Teijin Pharma Ltd | Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania |
HUP0103188A2 (hu) | 1998-08-07 | 2001-12-28 | Emisphere Technologies, Inc. | Vegyületek és készítmények hatóanyagok célbajuttatására |
CN1338924A (zh) | 1999-01-08 | 2002-03-06 | 艾米斯菲尔技术有限公司 | 聚合物输送剂和输送剂化合物 |
DE19903275A1 (de) | 1999-01-28 | 2000-08-03 | Merck Patent Gmbh | Lyophilisate mit verbesserter Rekonstituierbarkeit |
ATE309197T1 (de) | 1999-02-05 | 2005-11-15 | Emisphere Tech Inc | Verfahren zur herstellung alkylierter salicylamide |
EP1163209A4 (en) | 1999-02-26 | 2004-12-29 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS |
DE60017888T2 (de) * | 1999-04-05 | 2006-01-19 | Emisphere Technologies, Inc. | Dinatrium-salze, monohydrate und ethanol-solvate |
GB9923934D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Plc | Novel pharmaceutical |
GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
NZ530450A (en) | 1999-11-05 | 2004-06-25 | Emisphere Tech Inc | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
JP2001240581A (ja) * | 2000-02-29 | 2001-09-04 | Senju Pharmaceut Co Ltd | アミノベンズアミド誘導体およびその用途 |
JP4799794B2 (ja) | 2000-03-21 | 2011-10-26 | エミスフェアー・テクノロジーズ・インク | ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。 |
MXPA02012855A (es) | 2000-06-29 | 2004-04-20 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
JP4508646B2 (ja) | 2002-01-09 | 2010-07-21 | エミスフェアー・テクノロジーズ・インク | 4−[(4−クロロ−2−ヒドロキシベンゾイル)アミノ]ブタン酸ナトリウムの多形体 |
-
2003
- 2003-01-09 JP JP2003557970A patent/JP4508646B2/ja not_active Expired - Fee Related
- 2003-01-09 EP EP10012220A patent/EP2272501B1/en not_active Expired - Lifetime
- 2003-01-09 ES ES03719286.1T patent/ES2664189T3/es not_active Expired - Lifetime
- 2003-01-09 EP EP03719286.1A patent/EP1469827B1/en not_active Expired - Lifetime
- 2003-01-09 ES ES10012220T patent/ES2412306T3/es not_active Expired - Lifetime
- 2003-01-09 US US10/501,205 patent/US7227033B2/en not_active Expired - Lifetime
- 2003-01-09 CA CA2471144A patent/CA2471144C/en not_active Expired - Lifetime
- 2003-01-09 WO PCT/US2003/000878 patent/WO2003057650A2/en active Application Filing
- 2003-01-09 AU AU2003223158A patent/AU2003223158B2/en not_active Ceased
-
2005
- 2005-07-14 US US11/183,039 patent/US7208178B2/en not_active Expired - Lifetime
-
2007
- 2007-03-14 US US11/686,341 patent/US7462368B2/en not_active Expired - Lifetime
- 2007-04-12 US US11/734,591 patent/US7420085B2/en not_active Expired - Lifetime
-
2008
- 2008-07-02 US US12/167,126 patent/US7893297B2/en not_active Expired - Fee Related
-
2011
- 2011-07-12 HK HK11107242.8A patent/HK1153136A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2471144A1 (en) | 2003-07-17 |
US7227033B2 (en) | 2007-06-05 |
US20090010882A1 (en) | 2009-01-08 |
US20050272639A1 (en) | 2005-12-08 |
US7208178B2 (en) | 2007-04-24 |
JP2005520803A (ja) | 2005-07-14 |
US20080033204A1 (en) | 2008-02-07 |
US7420085B2 (en) | 2008-09-02 |
AU2003223158B2 (en) | 2008-01-17 |
US7462368B2 (en) | 2008-12-09 |
ES2412306T3 (es) | 2013-07-11 |
WO2003057650A2 (en) | 2003-07-17 |
AU2003223158A1 (en) | 2003-07-24 |
EP1469827A2 (en) | 2004-10-27 |
JP4508646B2 (ja) | 2010-07-21 |
ES2664189T3 (es) | 2018-04-18 |
US7893297B2 (en) | 2011-02-22 |
EP1469827A4 (en) | 2006-08-16 |
US20070161708A1 (en) | 2007-07-12 |
US20050250852A1 (en) | 2005-11-10 |
WO2003057650A3 (en) | 2003-10-16 |
EP2272501B1 (en) | 2013-03-20 |
EP1469827B1 (en) | 2017-12-27 |
CA2471144C (en) | 2011-06-07 |
EP2272501A1 (en) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1153136A1 (xx) | ||
HRP20040710A2 (en) | Antibody-containing solution pharmaceuticals | |
AU2003243096A1 (en) | NOVEL PURINE- OR PYRROLOL(2,3-d)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY | |
ZA200502406B (en) | Sustained released delivery of amphetamine salts. | |
HK1078568A1 (en) | 2-(2,6-dichlorophenyl)-diarylimidazoles | |
IL157254A0 (en) | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists | |
EP1572101A3 (en) | Disease treatment via antimicrobial peptide inhibitors | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
HK1076816A1 (xx) | ||
IL169184A0 (en) | Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents | |
AU2003212310A1 (en) | (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors | |
MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
EP1552826A4 (en) | AMINO ACID COMPOSITIONS TO IMPROVE CENTRAL FUNCTIONS | |
AU2003249535A1 (en) | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors | |
WO2005065047A3 (en) | Stable oral composition containing desloratadine | |
EP1549346A4 (en) | MODIFIED RECOMBINANT CELLS (ARCS) FOR THE PRODUCTION AND DISTRIBUTION OF ANTIVIRAL AGENTS, ADJUVANTIES AND VACCINE ACCELERATORS | |
EP1568704A4 (en) | NOVEL 2 ', 5'-OLIGOADENIC ACID ANALOG | |
GB2416123A (en) | Stable carprofen composition | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
AU2003209437A1 (en) | Amine oxides as perfume solubility agents | |
AU2003250465A1 (en) | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors | |
AU2003257407A1 (en) | S-(+)-3-{1-(2-(2,3-dihydro-1h-indol-3-yl)ethyl)-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof | |
WO2004056306A3 (de) | Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen | |
EP1486208A4 (en) | NEW PREVENTIVE TREATMENT AGAINST INFECTIONS | |
WO2004051549A8 (en) | Active agent delivery method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180109 |